Extrapulmonary Neuroendocrine Carcinoma — An Interview with Dr Jonathan Strosberg on Current and Future Management (Companion Faculty Lecture)
Research To Practice | Oncology Videos
00:00
Immunotherapy in Later Lines: Response Rates and Durability
Strosberg reviews second‑line immunotherapy trials showing modest response rates and rare durable responders.
Play episode from 13:48
Transcript
